Printer Friendly

ISIS RECEIVES PATENT FOR INTERMEDIATES USED IN ENZYME RESISTANT OLIGONUCLEOTIDES

 CARLSBAD, Calif., July 6 /PRNewswire/ -- Isis Pharmaceuticals Inc. (NASDAQ: ISIP) today announced that a United States Patent has been issued to the company for certain novel nucleoside compounds useful in the synthesis of enzyme resistant synthetic oligonucleotides.
 U.S. Patent 5,223,618 for "4'-Desmethyl Nucleoside Analog Compound" grants to Isis Pharmaceuticals Inc. patent protection for certain novel nucleoside compounds used to make a member of a new class of compound termed "oligonucleosides." Fundamentally different from existing oligonucleotides, this new class of oligonucleosides incorporates an ethylene glycol in place of a phosphate in the backbone, resulting in both improved resistance to cellular enzyme degradation and the absence of a negative charge.
 "Naturally occurring oligonucleotides, phosphodiesters, are degraded rapidly in the body by nucleases and, as a result, do not make good drugs. One important characteristic we build into oligonucleotide analogs is resistance to enzymatic degradation, to increase the stability of the compound and make it more desirable as a drug. This patent provides important chemical intermediates for a previously unknown class of synthetic oligonucleosides having improved enzymatic stability," said Stanley Crooke, M.D., Ph.D., chairman and chief executive officer of Isis. Four U.S. Patents have been issued to Isis in the past two months, enhancing the company's strong patent position in novel chemical intermediates and manufacturing methods useful in the development of oligonucleotide drugs.
 Isis Pharmaceuticals Inc., based in northern San Diego County, is engaged in the discovery and development of novel oligonucleotide-based human therapeutic compounds, a new chemical class and has multiple compounds in preclinical development. The company's first oligonucleotide-based drug for human papillomavirus, ISIS 2105, is in pivotal Phase II clinical trials.
 -0- 7/6/93
 /CONTACT: Jacqueline Siegel, Ph.D., of Isis Pharmaceuticals, 619-931-9200; or Lorraine Ruff of Stoorza Ziegaus & Metzger, 619-236-1332, for Isis Pharmaceuticals/
 (ISIP)


CO: Isis Pharmaceuticals Inc. ST: California IN: MTC SU: PDT

MF-JL -- SD001 -- 8527 07/06/93 09:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 6, 1993
Words:320
Previous Article:PIERRE SALINGER JOINS GLOBAL TELEWORKS BOARD OF DIRECTORS
Next Article:KEY TRONIC: FTC HAS NO OBJECTION TO PROPOSED ACQUISITION OF HONEYWELL'S KEYBOARD DIVISION
Topics:


Related Articles
ISIS PHARMACEUTICALS ANNOUNCES ISSUANCE OF ANTISENSE PATENT
ISIS PHARMACEUTICALS TO RECEIVE HIV ANTISENSE PATENT
TWO U.S. PATENTS ISSUED THAT ENHANCE ISIS' PROPRIETARY POSITION IN OLIGONUCLEOTIDE-BASED DRUG MANUFACTURING
U.S. PATENT ISSUES THAT EXPANDS ISIS' PROPRIETARY POSITION IN OLIGONUCLEOTIDE-BASED DRUG MANUFACTURING
ISIS PHARMACEUTICAL STRENGTHENS PROPRIETARY POSITION WITH FOUR PATENT APPROVALS
ISIS PHARMACEUTICALS RECEIVES FOUR PATENT ALLOWANCES FOR NOVEL ANTISENSE CHEMISTRY
Isis Receives Thirteen Patents Covering Antisense Biology, Chemistry and Combinatorial Chemistry
ISIS obtains United States patent.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters